作者: Jinyoung Yoo , Robert A. Robinson
DOI: 10.1002/(SICI)1097-0142(19990701)86:1<58::AID-CNCR10>3.0.CO;2-S
关键词: Carcinogenesis 、 Mutation 、 Medicine 、 Internal medicine 、 Soft tissue sarcoma 、 Tumor progression 、 Oncology 、 Sarcoma 、 Rhabdomyosarcoma 、 Point mutation 、 Cancer 、 Pathology
摘要: BACKGROUND The authors' recent investigation of Korean patients with sarcoma has suggested that ras gene activation may play a role in oncogenesis. The authors attempted to extend the mutation analysis sarcomas American determine whether there were racial or geographic factors relevant initiation progression sarcoma. METHODS H-ras and K-ras genes examined obtained from midwestern U. S. using polymerase chain reaction technique direct automated sequencing analysis. Tumors studied included 29 malignant fibrous histiocytomas, 7 liposarcomas, 5 rhabdomyosarcomas, 9 leiomyosarcomas. RESULTS Of 50 evaluated, only 1 (2%) definable was found; GGC AGC transition at codon 12 H-ras found rhabdomyosarcoma. None had mutation. rates incidence point mutations these samples much lower (H-ras: 2%; 95% confidence interval [95% CI], 0-11.5% K-ras: 0%) than described for both studies 16%; CI, 5.2-26.8% 44%; 29.5-58.5%). CONCLUSIONS Although reason this discrepancy is not clear, no major differences histology clinical stages. Based on study previous 45 tumor samples, conclude differing genetic and/or environmental mechanisms can affect development progression. Mutation appears be uncommon occurring patients, suggesting by does significant pathogenesis patients. Cancer 1999;86:58–63. © 1999 Society.